Hormonal
Testosterone therapy is conditionally recommended for postmenopausal women with properly diagnosed hypoactive sexual desire disorder (HSDD) to achieve midnormal premenopausal levels, with monitoring for androgen excess.
If you are postmenopausal and have been diagnosed with HSDD, a trial of physiological testosterone may be considered. The goal is to reach midnormal premenopausal levels, not supraphysiological ones. You must be monitored closely for signs of androgen excess, and therapy should be stopped if there is no response within 6 months.
We suggest a 3- to 6-month trial of a dose of T for postmenopausal women who request therapy for properly diagnosed HSDD and in whom therapy is not contraindicated resulting in a midnormal premenopausal value in a reference assay to avoid pharmacological T administration.
Why this rating
Based on short-term efficacy and safety data, but limited by lack of long-term studies and availability of approved preparations.
Source
Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline
Margaret E. Wierman et al. · The Journal of Clinical Endocrinology & Metabolism · 2014
DOI 10.1210/jc.2014-2260
More from this paper
- Testosterone therapy is not recommended for healthy women or those with conditions other than hypoactive sexual desire disorder (HSDD) due to lack of defined syndrome, unclear correlation between levels and symptoms, and insufficient long-term safety data.Weak
- Dehydroepiandrosterone (DHEA) is not recommended for general use in women due to inadequate indications and lack of evidence for efficacy and long-term safety.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →